Ranbaxy Halts Shipments From Two Plants Already Blocked By U.S. FDA
This article was originally published in PharmAsia News
Executive Summary
Ranbaxy Laboratories has stopped all shipments from two of its India plants that had been banned for exporting to the U.S., but had been allowed to continue to produce for India and other countries.